Evommune Competitors and Similar CompaniesClear all

Evommune's competitors and similar companies include Gilead Sciences and Athenex.
Evommune
Evommune
Evommune is a biotechnology company that provides inflammatory disease treatment.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
Athenex
Athenex
Athenex is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of cancer.
Founding Date
Founding Date
2020
Founding Date
1987
Founding Date
2003
Type
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Palo Alto, US HQ
Locations
Foster City, US HQ
Buenos Aires, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Buffalo, US HQ
Guatemala, GT
Alderley Edge, GB
see more
Employees
Employees
4521% decrease
Employees
18,0006% increase
Employees
575
Valuation ($)
Valuation ($)
N/A
Valuation ($)
110.5 b
Valuation ($)
2.3 m

Financial

Revenue (est.)
Revenue (est.)
$13m (FY, 2025)
Revenue (est.)
$29.4b (FY, 2025)
Revenue (est.)
$102.8m (FY, 2022)
Cost of goods
Cost of goods
N/A
Cost of goods
$6.2b (FY, 2025)
Cost of goods
$76.1m (FY, 2022)
Gross profit
Gross profit
N/A
Gross profit
$23.2b (FY, 2025)
Gross profit
$26.7m (FY, 2022)
Net income
Net income
($68.9m) (FY, 2025)
Net income
$8.5b (FY, 2025)
Net income
($104.4m) (FY, 2022)

Funding

Total funding raised
Total funding raised
$ 57.5m
Total funding raised
N/A
Total funding raised
$ 252.1m
For sources of this data, please see the company profile

View Company Profiles

Gilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.

View company
Athenex
HQ
Buffalo, US
Employees
575

Athenex is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of cancer.

View company